A Reliable Partner for Oncology CMO Projects: Servier’s OEB4 High-Containment Production Line

by Maela Casciello

November 19, 2026 News

Cancer is the second leading cause of death worldwide, and its incidence continues to rise. To address this growing challenge, innovative therapies such as targeted treatments are advancing rapidly. Alongside this progress, high-potency active pharmaceutical ingredients are appearing more frequently in pharmaceutical R&D pipelines.

These high-potency compounds can deliver strong therapeutic effects at extremely low doses, placing stringent requirements on containment during manufacturing. Conventional production lines may not always provide the containment measures required for compounds classified under higher Occupational Exposure Bands (OEBs). As a result, the industry is increasingly seeking reliable and operationally proven CMO services capable of supporting high-potency drug manufacturing.


Oncology is one of Servier’s long-standing core areas of innovation.

At Servier’s Tianjin manufacturing site in China, this industrial expertise is supported by dedicated capabilities for oral solid dosage manufacturing, including OEB4 operations for eligible projects. This expertise translates into a strong understanding of manufacturing processes, risk management and operational efficiency for CMO projects.

To address the specific requirements of highly potent and anti-cancer products, we have established dedicated production lines equipped with advanced technologies and containment systems. Choosing Servier CMO means gaining access to specialized, high-quality manufacturing and cost-competitive services designed to support the industrialization, technology transfer and commercial manufacturing of eligible oncology products.

To meet the stringent manufacturing requirements of highly potent compounds, our OEB4 high-containment production line at the Tianjin manufacturing site, offering the following key advantages:

  • High-Containment System

With containment capabilities reaching the OEB4 level, the line effectively controls exposure and contamination risks, providing a safe “isolated environment” for high-potency active ingredients.

  • Strict Safety Standards

From engineering controls and standard operating procedures to personal protective measures, a multi-layered protection system supports safe and compliant operations.

  • Dedicated Line Design

The line uses dedicated areas and dedicated equipment, physically separated from other product lines to eliminate contamination risks at the source.

  • Advanced Capacity

Equipped with world-class manufacturing and packaging equipment, the line supports efficient and reliable operations for eligible commercial-scale projects.

In the field of high-potency drugs, safety itself is a core competitive advantage.

Servier’s Tianjin dedicated OEB4 high-containment line can support a wide range of eligible oncology CMO projects. Whether for small-molecule targeted therapies or other high-potency oral solid dosage products, our teams provide specialized manufacturing capabilities supported by OEB4 containment measures.


Contact our team to learn more about our OEB4 capabilities and discuss the specific requirements of your high-potency manufacturing project.